Pfizer Inc. announced that it has initiated a phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition for COVID-19 in Paediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Pfizer
Found this useful? Share it with your team.
